Amelioration effects of berberine on diabetic microendothelial injury model by the combination of high glucose and advanced glycation end products in vitro

European Journal of Pharmacology

Volumn 654, Issue 3, 2011, Pages 320-325

  Hao, Min ^a   Li, Shu Yuan ^a   Sun, Chang Kai ^a   Jingyu Xu, ^a   Lin, Yuan ^a   Liu, Ke Xin ^a   Wang, Li ^a   Li, Chuan Xun ^a   Zhou, Qin ^a   Du, Jian Ling ^a   Li, Hua ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Berberine; Diabetes; Microendothelial cell; Thrombomodulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BERBERINE; GLUCOSE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOMODULIN;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BERBERINE; CELL EXTRACTS; CELL LINE; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOMODULIN; VASCULAR SYSTEM INJURIES;

EID: 79951670729     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.12.030     Document Type: Article

References (32)

1. N. Ahmed Advanced glycation endproducts: role in pathology of diabetic complications Diabetes Res Clin Pract 67 2005 3 21 (Pubitemid 40037725)
2. S. Chesne, P. Rondeau, S. Armenta, and E. Bourdon Effects of oxidative modifications induced by the glycation of bovine serum albumin on its structure and on cultured adipose cells Biochimie 88 2006 1467 1477 (Pubitemid 44687449)
3. A.T. Cheung, M.M. Tomic, P.C. Chen, E. Miguelino, C.S. Li, and S. Devaraj Correlation of microvascular abnormalities and endothelial dysfunction in Type-1 Diabetes Mellitus (T1DM): a real-time intravital microscopy study Clin. Hemorheol. Microcirc. 42 2009 285 295
4. M.S. Choi, J.H. Oh, and S.M. Kim Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells Int. J. Oncol. 34 2009 1221 1230
5. M.P. Cohen, G.T. Lautenslager, E. Hud, E. Shea, A. Wang, S. Chen, and C.W. Shearman Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal in-sufficiency Am J Physiol Renal Physiol 292 2007 F789 F795
6. S. Crikis, X.M. Zhang, S. Dezfouli, K.M. Dwyer, L.M. Murray-Segal, E. Salvaris, C. Selan, S.C. Robson, H.H. Nandurkar, P.J. Cowan, and A.J. d'Apice Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice Am. J. Transplant. 10 2010 242 250
7. T.M. Curtis, T.A. Gardiner, and A.W. Stitt Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye 23 2009 1496 1508
8. M. David-Dufilho, Brussel E. Millanvoye-Van, G. Topal, L. Walch, A. Brunet, and F. Rendu Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II J. Biol. Chem. 280 2005 35999 36006 (Pubitemid 41633869)
9. S. Devaraj, A.T. Cheung, I. Jialal, S.C. Griffen, D. Nguyen, N. Glaser, and T. Aoki Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications Diabetes 56 2007 2790 2796 (Pubitemid 350044923)
10. K.C. Donaghue, F. Chiarelli, D. Trotta, J. Allgrove, and K. Dahl-Jorgensen Microvascular and macrovascular complications associated with diabetes in children and adolescents Pediatr Diabetes 10 Suppl 12 2009 195 203
11. C.T. Esmon Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface FASEB J. 9 1995 946 955
12. C. Esposito, H. Gerlach, J. Brett, D. Stern, and H. Vlassara Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties J. Exp. Med. 170 1989 1387 1407 (Pubitemid 19250701)
13. S.Y. Goh, and M.E. Cooper Clinical review: the role of advanced glycation end products in progression and complications of diabetes J. Clin. Endocrinol. Metab. 93 2008 1143 1152 (Pubitemid 351519698)
14. A. Goldin, J.A. Beckman, A.M. Schmidt, and M.D. Creager Advanced glycation endproducts: sparking the development of diabetic vascular injury Circulation 114 2006 597 605 (Pubitemid 44199649)
15. C.G. Huang, Z.L. Chu, S.J. Wei, H. Jiang, and B.H. Jiao Effect of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells Thrombosis Res 106 2002 223 227 (Pubitemid 35248055)
16. H.Y. Kim, and K. Kim Protein glycation inhibitory and antioxidative activities of some plant extracts in vitro J. Agric. Food Chem. 51 2003 1586 1591
17. R. Kisugi, T. Kouzuma, T. Yamamoto, S. Akizuki, H. Miyamoto, Y. Someya, J. Yokoyama, I. Abe, N. Hirai, and A. Ohnishi Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin Clin. Chim. Acta 382 2007 59 64 (Pubitemid 46782738)
18. W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, S. Wang, J. Wu, Y. Wang, Z. Li, J. Liu, and J.D. Jiang Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat. Med. 10 2004 1344 1351 (Pubitemid 40022716)
19. P. Libby, D.M. Nathan, K. Abraham, J.D. Brunzell, J.E. Fradkin, S.M. Haffner, W. Hsueh, M. Rewers, B.T. Roberts, P.J. Savage, S. Skarlatos, M. Wassef, C. Rabadan-Diehl National Heart, Lung, and Blood Institute National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus Circulation 111 2005 3489 3493 (Pubitemid 40923404)
20. M.L. Lieuw-A-Fa, V.W. van Hinsbergh, T. Teerlink, R. Barto, J. Twisk, C.D. Stehouwer, and C.G. Schalkwijk Increased levels of N(epsilon)- (carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction Nephrol. Dial. Transplant. 19 2004 631 636 (Pubitemid 38263123)
21. S.A. Maroney, B.C. Cooley, R. Sood, H. Weiler, and A.E. Mast Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition J. Thromb. Haemost. 6 2008 111 117
22. M.L. Pedersen, J.L. Jacobsen, and A.R. Lynge Micro- and macrovascular complications among Greenlanders and Danes with type 2 diabetes mellitus in Nuuk, Greenland Int. J. Circumpolar Health 69 2010 195 207
23. K.C. Sourris, B.E. Harcourt, and J.M. Forbes A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches? Am. J. Nephrol. 30 2009 323 335
24. G. Suárez, R. Rajaram, A.L. Oronsky, and M.A. Gawinowicz Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose J. Biol. Chem. 264 1989 3674 3679 (Pubitemid 19072244)
25. S. Taddei, L. Ghiadoni, A. Virdis, D. Versari, and A. Salvetti Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies Curr. Pharm. Des. 9 2003 2385 2402 (Pubitemid 37236360)
26. N. Turner, J.Y. Li, A. Gosby, S.W. To, Z. Cheng, H. Miyoshi, M.M. Taketo, G.J. Cooney, E.W. Kraegen, D.E. James, L.H. Hu, J. Li, and J.M. Ye Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action Diabetes 57 2008 1414 1418
27. D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, and S. Taddei Endothelial dysfunction as a target for prevention of cardiovascular disease Diab. Care 32 Suppl 2 2009 S314 S321
28. C. Wang, J. Li, X. Lv, M. Zhang, Y. Song, L. Chen, and Y. Liu Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin Eur. J. Pharmacol. 620 2009 131 137
29. Y. Wang, Y. Huang, K.S. Lam, Y. Li, W.T. Wong, H. Ye, C.W. Lau, P.M. Vanhoutte, and A. Xu Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase Cardiovasc. Res. 82 2009 484 492
30. G. Wolf New insights into the pathophysiology of diabetic nephropathy:from haemodynamics to molecular pathology Eur. J. Clin. Invest. 34 2004 785 796 (Pubitemid 39657924)
31. B. Xu, Y. Ji, K. Yao, Y.X. Cao, and A. Ferro Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes Clin. Sci. (Lond) 109 2005 439 446 (Pubitemid 41640625)
32. J. Zhou, S. Zhou, J. Tang, K. Zhang, L. Guang, Y. Huang, Y. Xu, Y. Ying, L. Zhang, and D. Li Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats Eur. J. Pharmacol. 606 2009 262 268